153 related articles for article (PubMed ID: 38341350)
1. Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer's disease and related tauopathies.
Su J; Xiao Y; Wei L; Lei H; Sun F; Wang W; Yin J; Xiong R; Li S; Zhang P; Zhou Y; Wang X; Zheng J; Wang JZ
Sci Bull (Beijing); 2024 Apr; 69(8):1137-1152. PubMed ID: 38341350
[TBL] [Abstract][Full Text] [Related]
2. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies.
Zheng J; Tian N; Liu F; Zhang Y; Su J; Gao Y; Deng M; Wei L; Ye J; Li H; Wang JZ
Signal Transduct Target Ther; 2021 Jul; 6(1):269. PubMed ID: 34262014
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
4. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
5. Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies.
Tong BC; Huang AS; Wu AJ; Iyaswamy A; Ho OK; Kong AH; Sreenivasmurthy SG; Zhu Z; Su C; Liu J; Song J; Li M; Cheung KH
J Biomed Sci; 2022 Oct; 29(1):85. PubMed ID: 36273169
[TBL] [Abstract][Full Text] [Related]
6. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
7. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
[TBL] [Abstract][Full Text] [Related]
8. A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.
Sun H; Zhong Y; Zhu X; Liao H; Lee J; Chen Y; Ma L; Ren J; Zhao M; Tu M; Li F; Zhang H; Tian M; Ling D
ACS Nano; 2021 Mar; 15(3):5263-5275. PubMed ID: 33683854
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
Moore KBE; Hung TJ; Fortin JS
Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
[TBL] [Abstract][Full Text] [Related]
10. Pinning down phosphorylated tau and tauopathies.
Lim J; Lu KP
Biochim Biophys Acta; 2005 Jan; 1739(2-3):311-22. PubMed ID: 15615648
[TBL] [Abstract][Full Text] [Related]
11. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
[TBL] [Abstract][Full Text] [Related]
12. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
13. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
14. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
15. Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.
Almansoub HAMM; Tang H; Wu Y; Wang DQ; Mahaman YAR; Wei N; Almansob YAM; He W; Liu D
J Alzheimers Dis; 2019; 67(1):13-33. PubMed ID: 30507581
[TBL] [Abstract][Full Text] [Related]
16. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.
Iqbal K; Grundke-Iqbal I
Curr Drug Targets; 2004 Aug; 5(6):495-502. PubMed ID: 15270196
[TBL] [Abstract][Full Text] [Related]
19. Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.
Kimura T; Tsutsumi K; Taoka M; Saito T; Masuda-Suzukake M; Ishiguro K; Plattner F; Uchida T; Isobe T; Hasegawa M; Hisanaga SI
J Biol Chem; 2013 Mar; 288(11):7968-7977. PubMed ID: 23362255
[TBL] [Abstract][Full Text] [Related]
20. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models.
Wang W; Zhou Q; Jiang T; Li S; Ye J; Zheng J; Wang X; Liu Y; Deng M; Ke D; Wang Q; Wang Y; Wang JZ
Theranostics; 2021; 11(11):5279-5295. PubMed ID: 33859747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
